Significant Agreements - Neurocrine Collaboration receivables and contract liabilities (Details) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 31, 2019 Program	Mar. 31, 2023 USD ($) item	Dec. 31, 2023 USD ($) item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related party collaboration receivables, beginning balance		$ 257	$ 257
Related party collaboration receivables, ending balance			3,341
Neurocrine collaborative Agreement 2023 and Neurocrine Collaborative Agreement 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related party collaboration receivables, beginning balance		257	257
Additions			10,081
Deductions			(6,997)
Related party collaboration receivables, ending balance			3,341
Deferred revenue, beginning balance		$ 11,827	11,827
Additions			74,420
Deductions			(11,007)
Deferred revenue, ending balance			75,240
Neurocrine | Neurocrine Collaborative Agreement 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related party collaboration receivables, ending balance			$ 1,800
Number of discovery programs | item		3	3
Neurocrine | Neurocrine Collaborative Agreement 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue, ending balance			$ 6,100
Number of discovery programs	2		92,382
Discovery program 3 | Neurocrine | Neurocrine collaborative Agreement 2023 and Neurocrine Collaborative Agreement 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additions		$ 74,400
Deductions			$ 11,000